All In Biotech

Drug Trial Radar · NCT01595529

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

Last checked: Nov 20, 2026Latest source record: Aug 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 717 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

717

Actual

Start

May 18, 2012

Primary completion

Jun 30, 2019

Study completion Aug 12, 2019

Sponsor

Sponsor type
NIH
First posted
May 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 months, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The SCOUT study is a multi-center, centrally randomized, double-blind, placebo-controlled non-inferiority clinical trial. 746 participants will be enrolled over a 4.5 year period. 672 will be evaluated for the study's primary outcome measure. After the first 5 days of primary care physician initiated antimicrobial therapy, patients who are afebrile and asymptomatic will then be randomized (1:1) to the standard course therapy arm of 5 more days of the same antibiotic therapy or the short course therapy arm of a placebo for 5 more days (for 10 days total). The primary objective of this study is to determine if halting antimicrobial therapy in subjects who have exhibited clinical improvement 5 days after starting antibiotic therapy (short course therapy) have the same failure rate (symptomatic UTI) through visit Day 11-14 as subjects who continue to take antibiotics for an additional 5 days (standard course therapy).

Conditions

  • Urinary Tract Infection

Interventions

  • CefiximeDrug

    Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.

  • CephalexinDrug

    Cephalexin 50mg/kg/day in 3 divided doses

  • PlaceboOther

    Placebo to match the other four active treatments

  • Trimethoprim/SulfamethoxazoleDrug

    8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics.Time frame: Day 11 through Day 14
  2. Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. Per-protocol Population.Time frame: Day 11 through Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.